JP7809339B2 - 腸内微生物叢によりｓｃｆａ産生を促進する方法 - Google Patents

腸内微生物叢によりｓｃｆａ産生を促進する方法

Info

Publication number
JP7809339B2
JP7809339B2 JP2022523126A JP2022523126A JP7809339B2 JP 7809339 B2 JP7809339 B2 JP 7809339B2 JP 2022523126 A JP2022523126 A JP 2022523126A JP 2022523126 A JP2022523126 A JP 2022523126A JP 7809339 B2 JP7809339 B2 JP 7809339B2
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
probiotic
symprove
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553017A5 (https=
JP2022553017A (ja
Inventor
スミス，バリー
バトラー，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multigerm UK Enterprises Ltd
Original Assignee
Multigerm UK Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multigerm UK Enterprises Ltd filed Critical Multigerm UK Enterprises Ltd
Publication of JP2022553017A publication Critical patent/JP2022553017A/ja
Publication of JP2022553017A5 publication Critical patent/JP2022553017A5/ja
Priority to JP2025116425A priority Critical patent/JP2025163045A/ja
Application granted granted Critical
Publication of JP7809339B2 publication Critical patent/JP7809339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
JP2022523126A 2019-10-18 2020-10-16 腸内微生物叢によりｓｃｆａ産生を促進する方法 Active JP7809339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025116425A JP2025163045A (ja) 2019-10-18 2025-07-10 腸内微生物叢によりｓｃｆａ産生を促進する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201915144A GB201915144D0 (en) 2019-10-18 2019-10-18 Method of promoting SCFA production by gut microbiota
GB1915144.8 2019-10-18
PCT/GB2020/052621 WO2021074649A2 (en) 2019-10-18 2020-10-16 Methods of promoting scfa production by gut microbiota

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025116425A Division JP2025163045A (ja) 2019-10-18 2025-07-10 腸内微生物叢によりｓｃｆａ産生を促進する方法

Publications (3)

Publication Number Publication Date
JP2022553017A JP2022553017A (ja) 2022-12-21
JP2022553017A5 JP2022553017A5 (https=) 2023-10-20
JP7809339B2 true JP7809339B2 (ja) 2026-02-02

Family

ID=68728134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523126A Active JP7809339B2 (ja) 2019-10-18 2020-10-16 腸内微生物叢によりｓｃｆａ産生を促進する方法
JP2025116425A Withdrawn JP2025163045A (ja) 2019-10-18 2025-07-10 腸内微生物叢によりｓｃｆａ産生を促進する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025116425A Withdrawn JP2025163045A (ja) 2019-10-18 2025-07-10 腸内微生物叢によりｓｃｆａ産生を促進する方法

Country Status (12)

Country Link
US (1) US12419921B2 (https=)
EP (1) EP4044830A2 (https=)
JP (2) JP7809339B2 (https=)
CN (2) CN114745970B (https=)
AU (1) AU2020368684B2 (https=)
BR (1) BR112022007413A2 (https=)
CA (1) CA3154083A1 (https=)
DE (1) DE20796905T1 (https=)
ES (1) ES2922359T1 (https=)
GB (1) GB201915144D0 (https=)
MX (1) MX2022004382A (https=)
WO (1) WO2021074649A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN113875975B (zh) * 2021-09-03 2023-06-30 许昌学院 一种利用小麦加工副产物制备后生元的发酵工艺
WO2024216281A1 (en) * 2023-04-14 2024-10-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment of circadian rhythm disorders
WO2025217259A1 (en) * 2024-04-10 2025-10-16 Postbiotics Plus Research Llc Use of postbiotics for treating or preventing disruptions of the gut-brain axis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899872B1 (en) * 1995-11-27 2005-05-31 Standa Lab Sa Absorbable dietary composition for improving the biological balance of intestinal tract flora
GB2418431A (en) * 2004-09-27 2006-03-29 Multigerm Uk Entpr Ltd Metabolically active micro organisms and methods for their production
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
US9707207B2 (en) * 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
US10086018B2 (en) * 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) * 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
DK3329927T3 (da) * 2011-11-16 2023-12-11 Multigerm Uk Entpr Ltd IBS-behandling med probiotika
GB201219873D0 (en) * 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
US8889633B2 (en) * 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
WO2015159125A1 (en) * 2014-04-15 2015-10-22 Compagnie Gervais Danone Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after antibiotic dysbiosis
EP3639834B1 (en) * 2016-02-04 2023-07-12 Universiteit Gent Use of microbial communities for human and animal health
US10055534B2 (en) * 2016-03-17 2018-08-21 Applied Materials Israel Ltd. System and method for design based inspection
PL3443071T3 (pl) * 2016-04-11 2022-03-28 Wageningen Universiteit Nowe gatunki bakterii
US20180357375A1 (en) 2017-04-04 2018-12-13 Whole Biome Inc. Methods and compositions for determining metabolic maps
US11730749B2 (en) 2017-05-05 2023-08-22 Plexus Worldwide, Llc Compositions and methods for improving gut health
AU2018313765A1 (en) 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
AU2019216129B2 (en) * 2018-02-02 2022-03-17 Kobiolabs, Inc. Lactobacillus plantarum KBL396 strain and use thereof
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
FR3136482A1 (fr) * 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A four-strain probiotic exerts positive immunomodulatory effects by enhancing colonic butyrate production in vitro，International Journal of Pharmaceutics，Vol.555，2018年，p.1-10
Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial，Clinical Nutrition，2018年，38(3)，p.1031-1035
Efficacy of an oral probiotic (Symprove) on motor and non-motor symptoms in Parkinson’s disease: a novel randomised, double-blind, placebo-controlled study (SYM-PD)，King's College Hospital NHS，2019年04月19日，p.1-4
Journal ofNutritional Biochemistry，Vol.69，2019年04月06日，p.73-86

Also Published As

Publication number Publication date
ES2922359T1 (es) 2022-09-13
GB201915144D0 (en) 2019-12-04
US20230053778A1 (en) 2023-02-23
MX2022004382A (es) 2022-08-25
DE20796905T1 (de) 2022-11-24
AU2020368684A1 (en) 2022-05-19
CN114745970A (zh) 2022-07-12
CA3154083A1 (en) 2021-04-22
JP2025163045A (ja) 2025-10-28
WO2021074649A2 (en) 2021-04-22
JP2022553017A (ja) 2022-12-21
BR112022007413A2 (pt) 2022-07-05
CN118593548A (zh) 2024-09-06
AU2020368684B2 (en) 2026-02-12
US12419921B2 (en) 2025-09-23
WO2021074649A3 (en) 2021-07-22
EP4044830A2 (en) 2022-08-24
CN114745970B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
Benahmed et al. Association between the gut and oral microbiome with obesity
AU2022203731B2 (en) Use of pasteurized Akkermansia for treating metabolic disorders
JP7809339B2 (ja) 腸内微生物叢によりｓｃｆａ産生を促進する方法
Guida et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial
Tiihonen et al. Human intestinal microbiota and healthy ageing
TWI572354B (zh) 抑制發炎之組成物
KR20140000620A (ko) 장신경계의 개선을 위한 프로바이오틱 균주의 용도
Perazza et al. Distinct effects of milk-derived and fermented dairy protein on gut microbiota and cardiometabolic markers in diet-induced obese mice
US20250213600A1 (en) Composition for controlling growth of bacteria in the intestinal tract and use thereof
HK40109483A (zh) 液体非乳益生菌制剂治疗或预防帕金森病的用途
CN118870990A (zh) 用于控制肠道内的细菌的增殖的组合物及其用途
Okoye Yogurt Consumption and Exercise Improve Immunological Factors in Lactating Women
JP2026055457A (ja) ラクチプランチバチルス属乳酸菌を含む組成物
Altomare et al. The intestinal ecosystem and probiotics
EA041324B1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260114

R150 Certificate of patent or registration of utility model

Ref document number: 7809339

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150